Tokyo Stock Exchange · Healthcare
Invest in JCR Pharmaceuticals stock from India
Indian and foreign residents can buy JCR Pharmaceuticals (4552) shares directly through Paasa.
By Paasa · Updated
JCR Pharmaceuticals at a glance
- Price
- ¥515.00+¥14.00 (2.79%)
- Market cap
- ¥62.84B
- Day range
- ¥506.00 – ¥516.00
- P/E
- 76.64
- Dividend yield
- 3.88%
- Volume
- 410.90K
- 1 month
- -3.74%
- 6 months
- -12.41%
- YTD
- -25.47%
- 1 year
- -19.66%
- 5 years
- -82.30%
JCR Pharmaceuticals statements, FY2022–FY2026
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | ¥40.3B | ¥33.1B | ¥42.9B | ¥34.3B | ¥51.1B |
| Gross profit | ¥30.1B | ¥21.5B | ¥31.3B | ¥25.5B | ¥40.6B |
| Operating income | ¥431.0M | −¥6.8B | ¥7.5B | ¥5.0B | ¥19.9B |
| Net income | ¥2.2B | −¥4.8B | ¥5.5B | ¥3.8B | ¥14.5B |
| Earnings per share | ¥17.86 | −¥38.43 | ¥44.13 | ¥30.34 | ¥117.26 |
| EBITDA | ¥6.2B | −¥2.9B | ¥10.5B | ¥7.5B | ¥21.4B |
| Total assets | ¥109.2B | ¥105.5B | ¥102.7B | ¥95.4B | ¥97.5B |
| Total debt | ¥53.9B | ¥38.3B | ¥23.4B | ¥22.9B | ¥18.2B |
| Cash and short-term investments | ¥14.0B | ¥13.2B | ¥18.8B | ¥13.3B | ¥31.0B |
| Shareholders' equity | ¥46.9B | ¥47.0B | ¥56.2B | ¥52.2B | ¥50.9B |
| Operating cash flow | −¥135.0M | −¥5.5B | ¥9.3B | −¥5.5B | ¥9.3B |
| Free cash flow | −¥11.6B | −¥15.4B | ¥7.8B | −¥13.2B | −¥2.0B |
| Capital expenditure | −¥11.4B | −¥9.9B | −¥1.5B | −¥7.7B | −¥11.3B |
Fiscal years as reported, the latest ending 31 Mar 2026. Figures in JPY; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Nxera Pharma | 4565.T | ¥1,260.00 | ¥115.58B |
| Qol | 3034.T | ¥2,448.00 | ¥91.99B |
| Zeria Pharmaceutical | 4559.T | ¥2,035.00 | ¥89.70B |
| Shofu | 7979.T | ¥2,302.00 | ¥81.93B |
| Eiken Chemical | 4549.T | ¥2,391.00 | ¥78.82B |
| Medley | 4480.T | ¥2,349.00 | ¥70.58B |
| KYORIN | 4569.T | ¥1,140.00 | ¥65.49B |
| ASKA Pharmaceutical | 4886.T | ¥2,157.00 | ¥61.25B |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in JCR Pharmaceuticals from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to JPY when you buy.
Step 3
Search 4552 and buy
Find JCR Pharmaceuticals by name or by its ticker, 4552, and place your order. The Tokyo Stock Exchange typically trades in units of 100 shares.
Why invest in JCR Pharmaceuticals from India
What JCR Pharmaceuticals does
JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. JCR Pharmaceuticals operates in the Drug Manufacturers - General industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Here's what inheritance rules in Japan mean for your JCR Pharmaceuticals shares.
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir.
Frequently asked questions
Can I buy JCR Pharmaceuticals stock from India?
Yes. Indian residents and NRIs can buy JCR Pharmaceuticals (4552) shares directly through Paasa. JCR Pharmaceuticals is listed on the Tokyo Stock Exchange, in the Drug Manufacturers - General industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full JCR Pharmaceuticals share?
Usually more than one, and not a fraction: the Tokyo Stock Exchange typically trades in units of 100 shares. At ¥515.00 a share, size the order by the lot, not by the share.
How are JCR Pharmaceuticals dividends taxed for Indian investors?
Japan withholds a preferential 10% on dividends for Indian residents under the India–Japan DTAA rather than the higher domestic rate, and the tax withheld can be claimed as a foreign tax credit in India. Dividends are taxed at your slab rate in India. JCR Pharmaceuticals’ current yield is 3.88%. Paasa's dividend report lists the gross dividend and any tax withheld for each payment, which is what you need when you file.
What tax do I pay in India when I sell JCR Pharmaceuticals shares?
Japan generally does not levy capital gains tax on non-resident individual investors. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the JPY/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.
What happens to my JCR Pharmaceuticals shares if I pass away?
Japan levies inheritance tax on Japan-located assets such as direct stocks, with an exemption of ¥30 million plus ¥6 million per statutory heir. The rule looks at everything you hold there, not at JCR Pharmaceuticals alone.